ForteBio is now part of the Sartorius group. Click here for more

Towards a solution to MERS_protective human mAb targeting different domains and functions of the MERS-coronavirus spike glycoprotein

Ivy Widjaja, et al., 8(1): 516–530., Emerging Microbes and Infections 2019

The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions.

Read More

We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.